Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 42Fluorouracil 27Capecitabine 24pembrolizumab 21S 1 (combination) 19Paclitaxel 19Leucovorin 16Nivolumab 13Docetaxel 13sintilimab 12Drug Therapy 12Trastuzumab 11tislelizumab 10Cisplatin 10Irinotecan 9Bevacizumab 8trastuzumab deruxtecan 7spartalizumab 7XELOX 7Surgical Procedures, Operative 7Radiotherapy 7Hyperthermic Intraperitoneal Chemotherapy 7Biopsy 7fludarabine 6disitamab vedotin 6Cyclophosphamide 6lenvatinib 5apatinib 5Specimen Handling 5Ramucirumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Stomach Neoplasms × Paroxetine × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡